Quercetin loaded folate targeted plasmonic silver nanoparticles for light activated chemophotothermal therapy of DMBA induced breast cancer

Authors
Pritha Bose\textsuperscript{a}, Amiya Priyam\textsuperscript{b}, Rajiv Kar\textsuperscript{c} and Shakti P Pattanayak\textsuperscript{a,d*}

a) Division of Advanced Pharmacology, Department of Pharm. Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi- 835215

b) Department of Chemistry, School of Physical and Chemical Sciences, Central University of South Bihar, Gaya 823001, India

c) Fritz Haber Centre for Molecular Dynamic Research, Hebrew university of Jerusalem, Israel

d) Department of Pharmacy, School of Health Sciences, Central University of South Bihar, Gaya-824209, India

*Corresponding Author: Dr. Shakti P Pattanayak; Contact: +91-9123240698, 0651-2275444/896-Ext. 4832; E-mail: sppattanayak@cusb.ac.in, profsppattanayak@gmail.com

Emails: pritha2493@gmail.com, apriyam@cub.ac.in, rajivkarpharma@gmail.com
**Fig. 1(S)**

- **Group I**: Tumor induction (DMBA) → No drug treatment → Sacrifice
- **Group II**: Tumor induction (DMBA) → Treatment phase (28 days): AgNP → DMBA+AgNPs
- **Group III**: Tumor induction (DMBA) → Treatment phase (28 days): QRC → DMBA+QRC
- **Group IV**: Tumor induction (DMBA) → Treatment phase (28 days): Laser (NIR) → DMBA+Laser
- **Group V**: Tumor induction (DMBA) → Treatment phase (28 days): QRC-AgNP → DMBA+QRC-AgNPs
- **Group VI**: Tumor induction (DMBA) → Treatment phase (28 days): QRC-FA-AgNP → DMBA+QRC-FA-AgNPs
- **Group VII**: Tumor induction (DMBA) → Treatment phase (28 days): QRC-FA-AgNP + Laser (800 nm) irradiation → DMBA+QRC-FA-AgNPs + Laser

**Laser (800 nm) irradiation**